Chuck Royce's SLNO Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 129,043 shares of Soleno Therapeutics, Inc. (SLNO) worth $5.97 M, representing 0.06% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, Chuck Royce has maintained this position in SLNO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 98,056 shares. Largest reduction occurred in Q3 2025, reducing 69,711 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Soleno Therapeutics (SLNO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Soleno Therapeutics (SLNO) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +98,056 | Add 316.44% | 129,043 | $46.30 |
| Q3 2025 | -69,711 | Reduce 69.23% | 30,987 | $67.60 |
| Q2 2025 | +96,698 | Add 2417.45% | 100,698 | $83.78 |
| Q1 2025 | +4,000 | New Buy | 4,000 | $71.45 |
Chuck Royce's Soleno Therapeutics Investment FAQs
Chuck Royce first purchased Soleno Therapeutics, Inc. (SLNO) in Q1 2025, acquiring 4,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Soleno Therapeutics, Inc. (SLNO) for 4 quarters since Q1 2025.
Chuck Royce's largest addition to Soleno Therapeutics, Inc. (SLNO) was in Q4 2025, adding 129,043 shares worth $5.97 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 129,043 shares of Soleno Therapeutics, Inc. (SLNO), valued at approximately $5.97 M.
As of the Q4 2025 filing, Soleno Therapeutics, Inc. (SLNO) represents approximately 0.06% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Soleno Therapeutics, Inc. (SLNO) was 129,043 shares, as reported at the end of Q4 2025.